BioNTech SE American Depositary Share (BNTX) Earnings Date & Reports
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid... Show more
BNTX is expected to report earnings to rise 4.10% to -202 cents per share on August 04
BioNTech (BNTX) Q1 2026 Earnings Recap: Revenue Slumps Amid Oncology Push
Key Takeaways
- BioNTech reported Q1 2026 revenues of €118.1 million, down 35% from €182.8 million in Q1 2025, missing consensus estimates of approximately $207 million.
- Net loss widened to €531.9 million or €2.10 diluted loss per share (adjusted €1.95), compared to €415.8 million or €1.73 in the prior year; adjusted EPS beat expectations of around -$2.27.
- Cash, equivalents, and security investments stood at €16.8 billion as of March 31, 2026, providing ample runway for pipeline investments.
- Company announced a $1.0 billion share repurchase program over 12 months and plans manufacturing consolidations for ~€500 million annual savings by 2029.
- Reaffirmed 2026 guidance: revenues €2.0-2.3 billion, adjusted R&D €2.2-2.5 billion, adjusted SG&A €0.7-0.8 billion.
- Pipeline advances include five new pivotal trials for pumitamig (next-gen PD-1) with Bristol Myers Squibb and six late-stage readouts expected in 2026.
Earnings Context and Why It Matters
BioNTech's Q1 2026 earnings highlight the ongoing transition from COVID-19 vaccine dominance to an oncology-focused biotech powerhouse. With Comirnaty sales declining due to reduced demand and contract transitions in Europe, revenues fell sharply, underscoring the challenges in the post-pandemic era. This report matters for investors as it validates the company's pivot to immuno-oncology (IO) and antibody-drug conjugates (ADCs), backed by a €16.8 billion war chest. Prior quarters showed similar trends, with full-year 2025 revenues at €2.87 billion but swinging to losses amid R&D ramp-up. Broader biotech sector dynamics, including competitive vaccine markets and high IO trial costs, amplify scrutiny on BioNTech's ability to deliver pipeline catalysts amid margin pressures.
BioNTech reported total revenues of €118.1 million for the first quarter of 2026 (three months ended March 31, 2026), a 35% decline from €182.8 million in Q1 2025, primarily due to lower COVID-19 vaccine sales amid U.S. competition and European contract shifts. This missed analyst consensus of around $207 million (€~190 million).
The company posted a net loss of €531.9 million (€2.10 diluted loss per share), wider than €415.8 million (€1.73) last year, driven by R&D expenses of €557.0 million (up from €525.6 million) on IO/ADC programs and acquisitions like CureVac. Adjusted net loss was €494.6 million (€1.95/share), beating expectations of ~-$2.27/share. SG&A rose to €150.8 million from €120.6 million on commercial build-out.
Guidance was reaffirmed for 2026: revenues €2.0-2.3 billion (stable BMS collaboration, German contract, services), reflecting COVID headwinds offset by oncology potential. Cash remains robust at €16.8 billion. Key metrics show operating loss of €677 million (adjusted €640 million).
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across diverse portfolios. Explore the AI Screener today to uncover hidden gems in biotech and beyond.
Market Reaction and Investor Sentiment
BNTX shares fell sharply post-earnings, closing down 3.88% at $95.50 on May 5, 2026, after trading as low as $95.02, on volume of 1.38 million shares versus average 1.08 million. The drop reflected investor focus on the revenue miss and ongoing COVID revenue erosion, despite EPS beat, strong cash, buyback announcement, and reaffirmed guidance. Sentiment is mixed: optimism around oncology pipeline (e.g., pumitamig Phase 3s, six 2026 readouts) tempered by near-term losses and modest revenue outlook below prior peaks.
Forward Outlook and Key Factors to Monitor
BioNTech's 2026 priorities center on accelerating its late-stage oncology pipeline, with six key data readouts anticipated across immunomodulators, ADCs, and mRNA therapies. Pumitamig (BNT327, partnered with Bristol Myers Squibb) advances with five new Phase 3 trials in breast, colorectal, gastric, and lung cancers, plus Phase 2 NSCLC/SCLC data. Gotistobart's Phase 3 interim in squamous NSCLC and trastuzumab pamirtecan's BLA in endometrial cancer are pivotal.
Investors should watch pipeline execution, as successes could validate the IO/ADC shift. Manufacturing optimizations, including site exits affecting ~1,860 roles, target €500 million recurring savings by 2029 without disrupting supply. The $1 billion ADS buyback signals confidence in valuation disconnects.
Guidance implies stable non-COVID revenues but COVID declines; monitor variant-adapted vaccine approvals for 2026/2027. R&D (up slightly) and SG&A trends will gauge cost discipline amid €16.8 billion cash. Broader factors include BMS collaboration milestones, regulatory filings (e.g., trastuzumab pamirtecan), and M&A integration (CureVac, BioNTech China). Co-founders' transition to an independent mRNA entity by end-2026 bears watching for IP impacts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a company, which focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches
Industry Biotechnology